A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial compares the effect of using risk-based stratification to guide surgical management to the usual approach in treating cutaneous melanoma, atypical Spitz/Spitzoid tumors or other atypical melanocytic tumors that have not spread to other parts of the body (localized). Melanoma is a cancer that in children is sometimes difficult to tell apart from benign (not harmful) or atypical (uncertain if harmful) skin lesions. Failure to diagnose melanoma can result in inadequate surgical removal and increase the risk of recurrence and metastatic disease (spread from where it first started to other places in the body). In addition, diagnosing a tumor a benign (not cancer) tumor as cancer may lead to unnecessary surgery and treatment. This trial reviews tumor pathology and genetic markers and classifies the tumor as not atypical, atypical but low risk for spread and/or recurrence (coming back after a period of improvement), and atypical and high risk for spread and/or recurrence. The classifications are then used to provide surgical recommendations. Tumors that are not atypical do not receive any surgical treatment. Low-risk recommendations include removing a small layer of normal skin around the tumor. High-risk recommendations include the usual adult melanoma approach of removing a larger layer of normal skin around the tumor with or without a biopsy of the sentinel lymph node (the first lymph node to which tumor cells are likely to spread from a primary tumor). Risk-based guided surgical management may help avoid unnecessary surgery while improving outcomes in younger patients with localized cutaneous melanoma, atypical Spitz/Spitzoid tumors or other atypical melanocytic tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek do 25 lat
- •Nowo rozpoznany czerniak lub podejrzany czerniak ograniczony tylko do skóry
- •Choroba ograniczona do skóry potwierdzana badaniem klinicznym
- •Dobry stan ogólny (zdolność do codziennych aktywności)
✗ Disqualifies
- •Dorośli (18-25 lat) z tradycyjnym czerniakiem dorosłych - z wyjątkiem atypowych guzów Spitza
- •Nowotwór rozprzestrzenił się na inne części ciała
- •Pacjent już przeszedł rozszerzoną operację na tym guzie lub biopsję węzła chłonnego
- •Historia przeszczepienia narządu
Simplified criteria — AI translation
Trial details
- Maximum age
- 25 Years
- Last updated (source)
- September 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
Kaiser Permanente-Oakland
Oakland, United States
Alfred I duPont Hospital for Children
Wilmington, United States
Nemours Children's Clinic-Jacksonville
Jacksonville, United States
Nemours Children's Hospital
Orlando, United States
Nemours Children's Clinic - Pensacola
Pensacola, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Toledo, United States
Children's Hospital of Philadelphia
Philadelphia, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, United States
East Tennessee Childrens Hospital
Knoxville, United States
Saint Jude Children's Research Hospital
Memphis, United States
Dell Children's Medical Center of Central Texas
Austin, United States
UT MD Anderson Cancer Center
Houston, United States
Primary Children's Hospital
Salt Lake City, United States
Trial contact
Site Public Contact
Aarati V. Rao
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sridhi Patel
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jeffrey H. Schwartz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jamie L. Dargart
PRINCIPAL_INVESTIGATOR
Site Public Contact
Theodore W. Laetsch
PRINCIPAL_INVESTIGATOR
Site Public Contact
Brittani K. Seynnaeve
PRINCIPAL_INVESTIGATOR
Site Public Contact
Susan E. Spiller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alberto S. Pappo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shannon M. Cohn
PRINCIPAL_INVESTIGATOR
Site Public Contact
Najat C. Daw
PRINCIPAL_INVESTIGATOR
Site Public Contact
Casey J. Mehrhoff
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.